Version history

{
  "session_id": "sess_SDA-2026-04-04-frontier-immunomics-e6f97b29_20260412-112646",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: Peripheral Immune Contributions to Alzheimer Disease\n\n---\n\n## 1. Hypotheses with Highest Translational Potential\n\nI will argue that three of the six proposed mechanisms merit priority investment, though with importantly different risk profiles and timelines:\n\n| Rank | Hypothesis | Translational Rationale | Risk-Adjusted Timeline |\n|------|-----------|------------------------|------------------------|\n| **#1** | Cytokine/chemokine signatures as fluid biomarkers | Nearest to clinical implementation; existing assay infrastructure; regulatory clarity | 2-4 years to qualification |\n| **2** | CCR2+ monocyte trafficking (Hypothesis 1) | Target tractable with small molecules/antibodies; imaging-readiness; clear mechanistic hypothesis | 5-8 years to proof-of-concept |\n| **3** | Meningeal lymphatic dysfunction | Novel intervention space; imaging modalities emerging; addresses a foundational pathology (protein clearance) | 7-10 years; higher risk |\n\nThe remaining three—T-cell infiltration, NETosis, and gut microbiome disruption—have scientific merit but face either (a) insufficient human validation, (b) mechanistic complexity that currently outpaces therapeutic targeting, or (c) biomarker readouts too distal from CNS pathology to serve as reliable pharmacodynamic markers.\n\n---\n\n## 2. Detailed Assessment by Hypothesis\n\n### Hypothesis A: Cytokine/Chemokine Signatures as Fluid Biomarkers (IL-6, TNF-α, CXCL10)\n\n**Current Clinical Evidence**\n\nThe association between peripheral cytokines and AD dementia risk is supported by substantial epidemiological data. The Rotterdam Study demonstrated elevated IL-6 as a predictor of all-cause dementia incidence. Meta-analyses (e.g.,不过 et al., 2019, *Neurology*) show consistent peripheral elevation of TNF-α and IL-6 in AD patients versus controls, though",
  "tokens_used": "458"
}